Company profile
Aldeyra Therapeutics, Inc.
NASDAQ:ALDXBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Methotrexate | phase3 | — | 2 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (35)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07402876 | phase3 | recruiting | 2026-02-01 | 2026-12-01 | Aldeyra Therapeutics, Inc. | A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma |
| NCT06685692 | phase2 | completed | 2024-11-04 | 2025-06-18 | Aldeyra Therapeutics, Inc. | A Clinical Trial Investigating the Safety and Efficacy of Subjects With Alcohol Associated Hepatitis (Part 1) |
| NCT05717920 | phase2 | completed | 2023-02-15 | 2023-11-21 | Aldeyra Therapeutics, Inc. | A Clinical Trial in Subjects With Atopic Dermatitis (Part 1) |
| NCT04971031 | phase2 | completed | 2021-06-15 | 2021-09-08 | Aldeyra Therapeutics, Inc. | A Clinical Trial to Assess Subjects With Dry Eye Disease. |
| NCT06389214 | phase3 | completed | 2024-04-09 | 2024-06-11 | Aldeyra Therapeutics, Inc. | A Clinical Trial to Assess the Efficacy and Safety of Subjects With Dry Eye Disease |
FDA applications (0)
No records yet.